Morré D J, Wu L Y, Morré D M
Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN 47907, USA.
Biochim Biophys Acta. 1998 Mar 2;1369(2):185-92. doi: 10.1016/s0005-2736(97)00202-2.
In previous reports, our laboratory has described a drug-responsive NADH oxidase activity of the external surface of the plasma membrane of HeLa and other cancer cells, but not from normal cells, that was shed into media conditioned by the growth of cancer cells such as HeLa and also into sera of cancer patients. The sulfonylurea-altered activity was found in sera of a wide variety of cancer patients but the activity was either inhibited or stimulated by 1 microM LY181984. In this report, we demonstrate that one basis for whether or not the activity was stimulated or inhibited may be the redox environment of the protein. If plasma membrane vesicles from HeLa cells were first treated with dithiothreitol (DTT) or with reduced glutathione (GSH) and then assayed for NADH oxidase activity, the sulfonylurea inhibited the activity in a concentration-dependent manner. In contrast, if the plasma membrane vesicles were first treated with diluted hydrogen peroxide or oxidized glutathione (GSSG) and then assayed for NADH oxidase activity, the antitumor sulfonylurea stimulated the activity. Growth experiments were conducted in parallel. LY181984 administered to HeLa cells in the presence of GSH was approximately 2 log orders more effective than LY181984 administered to HeLa cells in the presence of GSSG. Similar results were found in the sera of cancer patients. With sera from normal individuals or with plasma membranes of rat liver, the oxidizing or reducing conditions were without effect. The findings suggest that the response of the cell surface NADH oxidase of HeLa cells to the antitumor sulfonylurea LY181984 is influenced by the redox environment which may determine whether the drug will stimulate or inhibit the activity and that the degree of response may be reflected in the ability of LY181984 to inhibit HeLa cell growth.
在之前的报告中,我们实验室描述了HeLa细胞和其他癌细胞质膜外表面存在一种药物反应性NADH氧化酶活性,而正常细胞没有,这种活性会释放到HeLa等癌细胞生长所条件化的培养基中,也会释放到癌症患者的血清中。在多种癌症患者的血清中发现了磺酰脲改变的活性,但该活性会被1 microM LY181984抑制或刺激。在本报告中,我们证明该活性被刺激或抑制的一个依据可能是蛋白质的氧化还原环境。如果先用二硫苏糖醇(DTT)或还原型谷胱甘肽(GSH)处理HeLa细胞的质膜囊泡,然后检测NADH氧化酶活性,磺酰脲会以浓度依赖的方式抑制该活性。相反,如果先用稀释的过氧化氢或氧化型谷胱甘肽(GSSG)处理质膜囊泡,然后检测NADH氧化酶活性,抗肿瘤磺酰脲会刺激该活性。同时进行了生长实验。在GSH存在下给予HeLa细胞的LY181984比在GSSG存在下给予HeLa细胞的LY181984效力高约2个对数级。在癌症患者的血清中也发现了类似结果。对于正常个体的血清或大鼠肝脏的质膜,氧化或还原条件没有影响。这些发现表明,HeLa细胞质膜NADH氧化酶对抗肿瘤磺酰脲LY181984的反应受氧化还原环境影响,这可能决定药物是刺激还是抑制该活性,并且反应程度可能反映在LY181984抑制HeLa细胞生长的能力上。